GWAG
SRPT icon

Garrett Wealth Advisory Group’s Sarepta Therapeutics SRPT Stock Holding History

Garrett Wealth Advisory Group’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-10
Closed -$753 – 559
2019
Q3 		$753 Buy
+10
New +$1.18K ﹤0.01% 748

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Garrett Wealth Advisory Group's SRPT Position: Q4 2019 in Review

Garrett Wealth Advisory Group sold out of Sarepta Therapeutics (SRPT) in Q4 2019, closing a stake of 10 shares — an estimated $753 sold.

Garrett Wealth Advisory Group first reported a position in SRPT in Q3 2019 and held it in 1 quarter. The position peaked at $753 in Q3 2019. 389 funds tracked by Wall St. Rank hold SRPT as of Q4 2019.

  • Garrett Wealth Advisory Group reported no remaining Sarepta Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Garrett Wealth Advisory Group sold 10 Sarepta Therapeutics shares in Q4 2019, an estimated $753.
  • Garrett Wealth Advisory Group first reported a position in Sarepta Therapeutics in Q3 2019 and held it in 1 quarter.
  • Garrett Wealth Advisory Group's Sarepta Therapeutics position peaked at $753 in Q3 2019.
  • 389 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2019.

Based on Garrett Wealth Advisory Group's 13F filing for Q4 2019, filed 28 Jan 2020.